Log in to your Inderes Free account to see all free content on this page.

Lumito

0.02 SEK

0.00 %

Less than 1K followers

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

0.00 %

-61.36 %

-79.91 %

-89.98 %

-92.05 %

-90.43 %

-96.90 %

-98.84 %

-96.51 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Market cap

29.25M SEK

Turnover

78.97K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

20.2.

2026

Annual report '25

7.5.

2026

General meeting '26

7.5.

2026

Interim report Q1'26

All

Press releases

ShowingAll content types

Regulatory press release12/5/2025, 1:15 PM

Nomination Committee for Lumito appointed ahead of the 2026 Annual General Meeting

Regulatory press release12/2/2025, 7:30 AM

Lumito Appoints Chief Business Officer to accelerate commercial growth

Regulatory press release11/27/2025, 7:30 AM

Lumito AB publishes interim report for the third quarter of 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/25/2025, 9:00 AM

Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report

Regulatory press release11/21/2025, 8:45 AM

Lumito granted SEK 250,000 business development grant from Region Skåne

Regulatory press release11/19/2025, 3:45 PM

Conversion of paid subscribed units (BTUs) and first day of trading in warrants of series TO7

Press release11/19/2025, 6:47 AM

BioStock: Video from Lumito's presentation at BioStock Life Science Summit 2025

Regulatory press release11/11/2025, 9:30 PM

Lumito's Board of Directors resolves on a directed share issue of units to guarantors in connection with the completed rights issue

Regulatory press release11/3/2025, 6:10 PM

Lumito announces outcome in rights issue

Regulatory press release10/29/2025, 8:30 AM

Truly Labs AB include Lumito’s tissue analysis technology into its customer offering

Regulatory press release10/27/2025, 7:30 AM

Last day of trading with unit rights in Lumito’s rights issue

Regulatory press release10/23/2025, 6:30 AM

Lumito AB and Katana Labs GmbH sign Letter of Intent and enter into a strategic partnership to enhance biomarker detection and quantification

Regulatory press release10/22/2025, 4:00 PM

Investor presentation from Financial Stockholm is now available

Regulatory press release10/17/2025, 11:15 AM

Lumito presents at Financial Stockholm on the 21st of October

Regulatory press release10/16/2025, 6:30 AM

The subscription period in Lumito’s rights issue of units starts today

Regulatory press release10/15/2025, 10:00 AM

Concept Life Sciences adds Lumito's tissue analysis solution to its customer offering following positive results from the SCIZYS platform evaluation

Regulatory press release10/13/2025, 9:50 AM

Lumito AB publishes prospectus in connection with rights issue of units of approximately SEK 60 million

Regulatory press release10/7/2025, 6:00 AM

Lumito AB announces terms of rights issue of units of approximately SEK 60 million

Regulatory press release10/3/2025, 1:10 PM

Lumito AB publishes white paper on the use of SCIZYS for high-sensitivity analysis of the breast cancer biomarker HER2 in tissue

Regulatory press release10/2/2025, 9:45 AM

Lumito AB at Biomarkers & Precision Medicine UK, NLSDays and Pharma Outsourcing

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.